Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.
It is a fully human pentameric IgM antibody with a mouse J chain.
Development
Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.
The mechanism of action is as a lipopolysaccharide inhibitor.
References